Cargando…

Exosomes loaded with programmed death ligand-1 promote tumor growth by immunosuppression in osteosarcoma

Osteosarcoma (OS) is a malignant tumor commonly observed in adolescents, who experience relapse and metastasis (30% of the total cases). Its progression is attributed to immune escape mediated by immune checkpoints. However, the intercellular connection between tumor cells and T cells remain unclear...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Lei, Xue, Lili, Wu, Yanjuan, Wu, Qilong, Ren, Hongwei, Song, Xiang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2021
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8810114/ https://www.ncbi.nlm.nih.gov/pubmed/34699324 http://dx.doi.org/10.1080/21655979.2021.1996509

Ejemplares similares

Thrombospondin‐1 induced programmed death‐ligand 1‐mediated immunosuppression by activating the STAT3 pathway in osteosarcoma
por: Liu, Zhuochao, et al.
Publicado: (2021)

Expression of programmed death ligand 1 in drug-resistant osteosarcoma: An exploratory study()()
por: Skertich, Nicholas J., et al.
Publicado: (2021)

Research Progress of Exosome-Loaded miRNA in Osteosarcoma
por: Yao, Peng, et al.
Publicado: (2022)

Osteoclast Immunosuppressive Effects in Multiple Myeloma: Role of Programmed Cell Death Ligand 1
por: Tai, Yu-Tzu, et al.
Publicado: (2018)

Targeting programmed cell death ligand 1 by CRISPR/Cas9 in osteosarcoma cells
por: Liao, Yunfei, et al.
Publicado: (2017)

Mesenchymal Stromal Cell Secretion of Programmed Death‐1 Ligands Regulates T Cell Mediated Immunosuppression
por: Davies, Lindsay C., et al.
Publicado: (2016)

Clinical outcome of osteosarcoma and its correlation with programmed death-ligand 1 and T cell activation markers
por: Yoshida, Kazushige, et al.
Publicado: (2019)

Exosomes and osteosarcoma drug resistance
por: Fu, Huichao, et al.
Publicado: (2023)

Tick saliva-induced programmed death-1 and PD-ligand 1 and its related host immunosuppression
por: Sajiki, Yamato, et al.
Publicado: (2021)

Effects of Tumor-Derived Exosome Programmed Death Ligand 1 on Tumor Immunity and Clinical Applications
por: Shao, Bo, et al.
Publicado: (2021)

Exosome-Mediated Immunosuppression in Tumor Microenvironments
por: Xie, Qi-Hui, et al.
Publicado: (2022)

Interferon-γ induces immunosuppression in salivary adenoid cystic carcinoma by regulating programmed death ligand 1 secretion
por: Fu, Qiuyun, et al.
Publicado: (2022)

Chemokine C‐C motif ligand 21 synergized with programmed death‐ligand 1 blockade restrains tumor growth
por: Chen, Qiangda, et al.
Publicado: (2021)

Programmed Cell Death Protein 1/Programmed Cell Death Protein Ligand 1 Immunosuppressants in Advanced Non-Small Cell Lung Cancer Research Progress in Treatment
por: Li, Feng, et al.
Publicado: (2022)

Liver kinase B1 in exosomes inhibits immune checkpoint programmed death ligand 1 and metastatic progression of intrahepatic cholangiocarcinoma
por: Liu, Zhuo, et al.
Publicado: (2022)

Programmed death ligand-1/programmed death-1 inhibition therapy and programmed death ligand-1 expression in urothelial bladder carcinoma
por: Yu, Wei-Bo, et al.
Publicado: (2019)

Prognostic Value of Programmed Cell Death 1 Ligand-1 (PD-L1) or PD-1 Expression in Patients with Osteosarcoma: A Meta-Analysis
por: Huang, Xin, et al.
Publicado: (2018)

Targeting programmed death ligand 2/repulsive guidance molecule b pathway: a novel strategy to subdue tumor immunotherapy resistance to anti‐programmed death 1/programmed death ligand 1
por: Xiang, Yuancai, et al.
Publicado: (2023)

Tumor-Derived Exosomes in Immunosuppression and Immunotherapy
por: Olejarz, Wioletta, et al.
Publicado: (2020)

Therapeutic Effects of Zoledronic Acid-Loaded Hyaluronic Acid/Polyethylene Glycol/Nano-Hydroxyapatite Nanoparticles on Osteosarcoma
por: Xu, Yan, et al.
Publicado: (2022)

Recent Findings in the Regulation of Programmed Death Ligand 1 Expression
por: Shen, Xiangfeng, et al.
Publicado: (2019)

Cancer-associated fibroblast infiltration in osteosarcoma: the discrepancy in subtypes pathways and immunosuppression
por: Zhihao, Zhang, et al.
Publicado: (2023)

Modulation of immunosuppressive cells and noncoding RNAs as immunotherapy in osteosarcoma
por: Xia, Yidan, et al.
Publicado: (2022)

LINC00244 suppresses cell growth and metastasis in hepatocellular carcinoma by downregulating programmed cell death ligand 1
por: Sun, Zhijia, et al.
Publicado: (2022)

Exosomal PD-L1 induces osteogenic differentiation and promotes fracture healing by acting as an immunosuppressant
por: Lin, Ze, et al.
Publicado: (2021)

Programmed death-ligand 1 signaling pathway involves in bladder cancer growth and progression
por: Samishina, Elena A., et al.
Publicado: (2019)

The incidence risk of programmed cell death-1/programmed cell death ligand 1 inhibitor-related alopecia for cancer patients: A systematic review and meta-analysis
por: Li, Mingkai, et al.
Publicado: (2020)

Clinical significance of programmed death 1/programmed death ligand 1 pathway in gastric neuroendocrine carcinomas
por: Yang, Min-Wei, et al.
Publicado: (2019)

Tumor-associated neutrophils activated by tumor-derived CCL20 (C-C motif chemokine ligand 20) promote T cell immunosuppression via programmed death-ligand 1 (PD-L1) in breast cancer
por: Kwantwi, Louis Boafo, et al.
Publicado: (2021)

Programmed death‐ligand 1 expression in swine chronic infections and enhancement of interleukin‐2 production via programmed death‐1/programmed death‐ligand 1 blockade
por: Ganbaatar, Otgontuya, et al.
Publicado: (2021)

Current Strategies for Exosome Cargo Loading and Targeting Delivery
por: Zeng, Haifeng, et al.
Publicado: (2023)

More insights into the immunosuppressive potential of tumor exosomes
por: Huber, Veronica, et al.
Publicado: (2008)

Radiotherapy Upregulates Programmed Death Ligand-1 through the Pathways Downstream of Epidermal Growth Factor Receptor in Glioma
por: Song, Xing, et al.
Publicado: (2018)

Astragaloside IV Attenuates Programmed Death-Ligand 1-Mediated Immunosuppression during Liver Cancer Development via the miR-135b-5p/CNDP1 Axis
por: Ma, Yang, et al.
Publicado: (2023)

Prognostic significance of programmed death-1 and programmed death-ligand 1 expression in patients with esophageal squamous cell carcinoma
por: Chen, Kaiyan, et al.
Publicado: (2016)

Exosomal PD-L1 functions as an immunosuppressant to promote wound healing
por: Su, Dandan, et al.
Publicado: (2019)

Extracellular Vesicles (Exosomes) as Immunosuppressive Mediating Variables in Tumor and Chronic Inflammatory Microenvironments
por: Awadasseid, Annoor, et al.
Publicado: (2021)

Exosomal and Soluble Programed Death-Ligand 1 (PD-L1) Predicts Responses to Pembrolizumab in Patients with Extranodal NK/T-Cell Lymphoma
por: Kim, Seok Jin, et al.
Publicado: (2022)

Effect of baricitinib in regulating programmed death 1 and ligand programmed cell death ligand 1 through JAK/STAT pathway in psoriasis
por: Deepak, H. B., et al.
Publicado: (2022)

Expression of programmed death ligand-1 predicts poor outcome in nasopharyngeal carcinoma
por: Li, Ying-Fei, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_vk6ttgj3la1ie9ifi54vpb2tst